adebrelimab + apatinib + gemcitabine + cisplatin

This is a four-drug combination regimen composed of: - **Adebrelimab**: a monoclonal antibody and immune checkpoint inhibitor targeting PD-L1, developed as immunotherapy for various cancers. - **Apatinib**: a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), impeding angiogenesis in tumors. - **Gemcitabine**: a nucleoside analog (antimetabolite) chemotherapeutic agent that inhibits DNA synthesis, used broadly in solid tumors. - **Cisplatin**: a platinum-based chemotherapy that induces DNA crosslinking and cell death, widely used for many types of cancer. The regimen is experimental for advanced cancers, and combines immunotherapy (adebrelimab), anti-angiogenic (apatinib), and cytotoxic chemotherapy (gemcitabine and cisplatin).

Brand names

GemCisGC

Other names

GCGemCis